What is the 13F Pro Quality Score for SNTI?

13F Pro ranks Senti Biosciences Holdings, Inc. (SNTI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNTI's current score at https://13fpro.ai/company/SNTI (free sign-up required for the full ranking).

Where does 13F Pro source SNTI data?

All Senti Biosciences Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Senti Biosciences Holdings, Inc. files with the SEC under CIK 1854270. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNTI in?

Senti Biosciences Holdings, Inc. (SNTI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNTI research updated on 13F Pro?

SNTI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Senti Biosciences Holdings, Inc.(SNTI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1854270 SNTI stock profile & AI dashboard →

13F Pro Quality Score

14.3/100

Rank #2,864 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SNTI Scores 14/100

exact factor attribution · 2026-09-11

SNTI's composite is driven by earnings growth, held back by free cash flow and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Earnings quality

-1.8 pts

32th pct

Institutional flow

-1.8 pts

14th pct

Shareholder dilution

-2.5 pts

0th pct

Capital efficiency

-4.6 pts

4th pct

Profitability

-6.8 pts

5th pct

Scale

-6.8 pts

5th pct

Revenue growth

-6.8 pts

16th pct

Free cash flow

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SNTI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Senti Biosciences Holdings, Inc. (SNTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SNTI at 14.3/100 on a 32-signal composite quality model, placing it at rank #2,864 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Senti Biosciences Holdings, Inc. reports quarterly revenue of $17.0K, net income of $-12.8M. Top institutional holders of SNTI by reported 13-F value include NEA Management Company, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. SNTI trades on the Nasdaq exchange and files with the SEC under CIK 1854270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Senti Biosciences Holdings, Inc. directly from SEC EDGAR. Senti Biosciences Holdings, Inc.'s 13F Pro composite quality score has ranged between 3 and 27 since 2023, currently 14.3 — a declining long-term trajectory across 10 quarterly and live scoring snapshots.

Revenue

Q2 2026

$17.0K

Net Income

Q2 2026

$-12.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$22.0KFY 2025

FY22 $4.3MFY23 $2.6MFY24 $0.00FY25 $22.0K

Net Income

-16.4% YoY

$-61.4MFY 2025

FY22 $-58.2MFY23 $-71.1MFY24 $-52.8MFY25 $-61.4M

Operating Income

-12.7% YoY

$-68.8MFY 2025

FY22 $-62.1MFY23 $-92.7MFY24 $-61.0MFY25 $-68.8M

EPS (Diluted)

+77.3% YoY

$-2.73FY 2025

FY22 $-0.22FY23 $-1.60FY24 $-12.03FY25 $-2.73

Total Assets

-47.6% YoY

$51.2MFY 2025

FY22 $180.8MFY23 $119.5MFY24 $97.8MFY25 $51.2M

Op. Cash Flow

-4.9% YoY

$-43.4MFY 2025

FY22 $-34.9MFY23 $-52.4MFY24 $-41.4MFY25 $-43.4M

Free Cash Flow

-5.4% YoY

$-43.6MFY 2025

FY22 $-76.3MFY23 $-64.4MFY24 $-41.4MFY25 $-43.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$22.0K	$0.00 -100.0%	$2.6M -40.2%	$4.3M +55.2%	$2.8M	—
Net Income	$-61.4M -16.4%	$-52.8M +25.7%	$-71.1M -22.1%	$-58.2M -5.2%	$-55.3M	—
Operating Income	$-68.8M -12.7%	$-61.0M +34.2%	$-92.7M -49.4%	$-62.1M -53.5%	$-40.4M	—
EPS (Diluted)	$-2.73 +77.3%	$-12.03 -651.4%	$-1.60 -617.9%	$-0.22 +88.3%	$-1.90	—
Total Assets	$51.2M -47.6%	$97.8M -18.1%	$119.5M -33.9%	$180.8M +87.0%	$96.7M	—
Operating Cash Flow	$-43.4M -4.9%	$-41.4M +21.0%	$-52.4M -50.1%	$-34.9M -0.8%	$-34.6M	—
Free Cash Flow	$-43.6M -5.4%	$-41.4M +35.7%	$-64.4M +15.5%	$-76.3M -89.8%	$-40.2M	—

Get alerted when SNTI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Senti Biosciences Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNTI

NEA Management Company, LLC
$4.2M3,775,615 sh
VANGUARD CAPITAL MANAGEMENT LLC
$591.3K537,504 sh
GEODE CAPITAL MANAGEMENT, LLC
$205.8K187,065 sh
CITADEL ADVISORS LLC
$117.8K107,100 sh
VANGUARD FIDUCIARY TRUST CO
$100.3K91,193 sh
JANE STREET GROUP, LLC
$57.8K52,530 sh
Menlo Ventures Management, L.P.
$39.3K35,737 sh
NORTHERN TRUST CORP
$35.4K32,154 sh
XTX Topco Ltd
$26.0K23,610 sh
Virtu Financial LLC
$25.0K22,795 sh

Fund	Value	Shares
NEA Management Company, LLC	$4.2M	3,775,615
VANGUARD CAPITAL MANAGEMENT LLC	$591.3K	537,504
GEODE CAPITAL MANAGEMENT, LLC	$205.8K	187,065
CITADEL ADVISORS LLC	$117.8K	107,100
VANGUARD FIDUCIARY TRUST CO	$100.3K	91,193
JANE STREET GROUP, LLC	$57.8K	52,530
Menlo Ventures Management, L.P.	$39.3K	35,737
NORTHERN TRUST CORP	$35.4K	32,154
XTX Topco Ltd	$26.0K	23,610
Virtu Financial LLC	$25.0K	22,795

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNTI on your watchlist

Track score changes the day Senti Biosciences Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNTI a good stock to buy?

13F Pro's AI-powered analysis of Senti Biosciences Holdings, Inc. (SNTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNTI are available on the SNTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SNTI is classified as a small company.

Which hedge funds own SNTI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Senti Biosciences Holdings, Inc.'s investment landscape.